HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

AuthorsThomas Powles, Toni K Choueiri, Robert J Motzer, Eric Jonasch, Sumanta Pal, Nizar M Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T Aftab, Bernard Escudier, Daniel J George
JournalBMC cancer (BMC Cancer) Vol. 21 Issue 1 Pg. 1023 (Sep 15 2021) ISSN: 1471-2407 [Electronic] England
PMID34525968 (Publication Type: Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: